NCT06050928

Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria

Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria (CALM-CIndU)

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 33 (actual)
• Sponsor: Escient Pharmaceuticals, Inc · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This phase 1b trial will evaluate the effects of EP262 in subjects with Chronic Inducible Urticaria (CIndU), including symptomatic dermographism and cold urticaria.

Conditions

• Chronic Inducible Urticaria

Interventions

Type	Name	Description
DRUG	Oral EP262	Once daily

Timeline

• Start date: 2023-08-30
• Primary completion: 2024-10-22
• Completion: 2024-10-22
• First posted: 2023-09-22
• Last updated: 2024-12-09

Locations

15 sites across 5 countries: United States, Canada, Germany, Netherlands, Spain

Regulatory

• FDA-regulated drug study